Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김수인 | * |
dc.date.accessioned | 2023-04-18T16:31:04Z | - |
dc.date.available | 2023-04-18T16:31:04Z | - |
dc.date.issued | 2023 | * |
dc.identifier.issn | 1738-1088 | * |
dc.identifier.issn | 2093-4327 | * |
dc.identifier.other | OAK-33278 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/265007 | - |
dc.description.abstract | Objective: To investigate the effects of long-acting injectable 3-monthly paliperidone palmitate on the clinical and social functioning of patients with schizophrenia. Methods: This study enrolled patients with schizophrenia receiving long-acting injectable 1-monthly paliperidone palmi-tate for at least 4 months and who subsequently received 3-monthly paliperidone palmitate. Accordingly, 418 patients were followed up for 24 weeks. Their clinical symptoms and social functioning were measured using the Clinical Global Impression-Severity of Illness and Personal and Social Performance scales. Results: The Personal and Social Performance total score was significantly higher after 3-monthly paliperidone palmitate treatment than at baseline (baseline vs. week 24: 54.3 +/- 18.0 vs. 61.0 +/- 14.5 [mean +/- standard deviation]; p < 0.001; Wilcoxon signed-rank test); the proportion of patients in the mildly ill group (scores 71-100) also increased significantly (baseline vs. week 24: 16.5% vs. 20.6%; p < 0.001; McNemar-Bowker test). The mean Clinical Global Impression-Severity of Illness score decreased significantly (baseline vs. week 24: 3.7 +/- 1.0 vs. 3.4 +/- 0.9; p < 0.001; Wilcoxon signed-rank test), as did the proportion of patients in the severely ill group (baseline vs. week 24: 4.1% vs. 2.1%; p < 0.001; McNemar-Bowker test). Conclusion: Continuous 3-monthly paliperidone palmitate treatment significantly enhances the personal and social per-formance of patients with schizophrenia and reduces the proportion of those with severe illness. These findings suggest that long-acting injectable antipsychotic administration at intervals longer than 1 month might improve the social func-tioning of and promote return to activities of daily living in patients with schizophrenia. | * |
dc.language | English | * |
dc.publisher | KOREAN COLL NEUROPSYCHOPHARMACOLOGY | * |
dc.subject | KEY WORDS | * |
dc.subject | Schizophrenia | * |
dc.subject | Antipsychotics | * |
dc.subject | Paliperidone palmitate | * |
dc.subject | Clinical global impression | * |
dc.subject | Personal and social performance | * |
dc.title | Effects of Long-acting Injectable 3-Monthly Paliperidone Palmitate on the Clinical and Social Performance of Patients with Schizophrenia | * |
dc.type | Article | * |
dc.relation.issue | 2 | * |
dc.relation.volume | 21 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.index | KCI | * |
dc.relation.startpage | 126 | * |
dc.relation.lastpage | 134 | * |
dc.relation.journaltitle | CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE | * |
dc.identifier.doi | 10.9758/cpn.2023.21.1.126pISSN1738-1088/eISSN2093-4327 | * |
dc.identifier.wosid | WOS:000928396500010 | * |
dc.author.google | Oh, Jihoon | * |
dc.author.google | Oh, Jihye | * |
dc.author.google | Kim, Dong Wook | * |
dc.author.google | Youn, HyunChul | * |
dc.author.google | Kim, Sae-Hoon | * |
dc.author.google | Kim, Soo In | * |
dc.author.google | Chung, In Won | * |
dc.author.google | Wang, Kuan Shu | * |
dc.author.google | Kim, Minah | * |
dc.author.google | Paik, Jong -Woo | * |
dc.author.google | Koh, Min Jung | * |
dc.author.google | Lee, Yoosun | * |
dc.author.google | Choi, Seok Young | * |
dc.author.google | Kim, Jung-Jin | * |
dc.contributor.scopusid | 김수인(54787809400) | * |
dc.date.modifydate | 20240123101016 | * |